Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology Reports Financial Results for Fourth Quarter and Full Year 2019
– Emergence of TCR program, Controlled IL-12 data, strengthened team highlight 2019 – – Balance sheet strengthened; cash of approximately $177 million funds operations to mid-2022 – – Clinical trial milestones and data readouts in 1H20 –   – Company to host conference call and webcast today at 4:30
View HTML
Toggle Summary Ziopharm Oncology Presentation at the Barclays Global Healthcare Conference to be Webcast
BOSTON , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at the Barclays Global Healthcare Conference in Miami on Wednesday, March 11, 2020
View HTML
Toggle Summary Ziopharm Oncology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Results on March 2, 2020
BOSTON , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, March 2 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the fourth quarter and year ended December
View HTML
Toggle Summary Ziopharm Oncology Announces Pricing of Public Offering of Common Stock
BOSTON , Feb. 05, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced the pricing of an underwritten public offering of 27,826,086 shares of its common stock at a public offering price of $3.25 per share. Ziopharm has granted the underwriters a 30-day option to purchase
View HTML
Toggle Summary Ziopharm Oncology Announces Proposed Public Offering of Common Stock
BOSTON , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Ziopharm.
View HTML
Toggle Summary Ziopharm Oncology Announces Recent Publications in Peer-Reviewed Scientific Journals
– Encouraging long-term outcome data after infusion of Sleeping Beauty -modified CAR-T published in Blood – – TCRs targeting mutations in TP53 obtained from T cells in peripheral blood to overcome need for surgical resection published in Clinical Cancer Research – BOSTON , Jan.
View HTML
Toggle Summary Ziopharm Oncology Presentation at the 38th Annual J.P. Morgan Healthcare Conference to be Webcast
BOSTON , Dec. 19, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at the 38 th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday,
View HTML
Toggle Summary Ziopharm Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON , Dec. 09, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP) today reported that the Company granted a new employee an option to purchase an aggregate of 65,000 shares of Ziopharm’s common stock effective November 21, 2019 .
View HTML
Toggle Summary Ziopharm Oncology Presents Pre-Clinical Data Validating “Rapid Personalized Manufacture” (RPM) with TCR at the 2019 American Society for Hematology Annual Meeting
– Membrane bound IL-15 (mbIL15) improves anti-tumor effect of TCR-modified T cells – – T cells expressing T-cell receptor (TCR) and mbIL15 can be infused day after gene transfer – BOSTON , Dec. 08, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq:ZIOP), today
View HTML
Toggle Summary Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting
– Controlled IL-12 evaluated as monotherapy in an expanded number of patients reinforced favorable safety profile and initial data consistent with immune-mediated anti-tumor effects – – Controlled IL-12 can be combined with full dose of a PD-1 inhibitor; favorable safety profile and initial data
View HTML